(BBH) VanEck Biotech - Ratings and Ratios
Biotechnology, Stocks, Depository Receipts, Medium-Cap
Dividends
| Dividend Yield | 0.66% |
| Yield on Cost 5y | 0.73% |
| Yield CAGR 5y | 19.79% |
| Payout Consistency | 74.3% |
| Payout Ratio | - |
| Risk via 10d forecast | |
|---|---|
| Volatility | 18.3% |
| Value at Risk 5%th | 31.1% |
| Relative Tail Risk | 3.51% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.58 |
| Alpha | 4.73 |
| CAGR/Max DD | 0.25 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.374 |
| Beta | 0.655 |
| Beta Downside | 0.602 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.74% |
| Mean DD | 6.79% |
| Median DD | 5.98% |
Description: BBH VanEck Biotech October 26, 2025
VanEck’s Biotech ETF (NASDAQ: BBH) tracks a benchmark that is at least 80 % weighted in U.S.-listed biotechnology stocks, including both common shares and depositary receipts. The index covers a mix of medium-cap firms and foreign companies listed in the U.S., and the fund is classified as non-diversified, meaning concentration risk can be higher than in broadly diversified ETFs.
Key sector drivers that can affect BBH’s performance include: (1) Biotech R&D intensity – U.S. biotech firms collectively spent roughly $95 billion on research and development in 2023, a figure that typically correlates with pipeline robustness; (2) Regulatory outcomes – the FDA’s approval rate for new molecular entities was 57 % in 2023, and any shift in this rate can materially swing earnings for the index constituents; (3) Macro-level demand – the global biotech market is projected to grow at a CAGR of about 10 % through 2028, driven by aging populations and increased adoption of gene-therapy platforms, which can boost revenue growth for the companies in BBH’s basket.
If you want a data-rich, side-by-side comparison of BBH’s risk-adjusted returns versus other health-care ETFs, a quick look at ValueRay’s analytics dashboard can help you surface the metrics that matter most.
What is the price of BBH shares?
Over the past week, the price has changed by -2.05%, over one month by +0.85%, over three months by +15.03% and over the past year by +16.77%.
Is BBH a buy, sell or hold?
What are the forecasts/targets for the BBH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 194.1 | 1.8% |
BBH Fundamental Data Overview December 03, 2025
Beta = 0.94
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 385.8m USD (385.8m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 385.8m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 385.8m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.43% (E(385.8m)/V(385.8m) * Re(8.43%) + (debt-free company))
Discount Rate = 8.43% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for BBH ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle